Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.

Bianca RaffaelliValeria MussettoHeike IsraelLars NeebUwe Reuter

Published in: The journal of headache and pain (2019)

In this small, self-selected cohort, the results indicate a therapeutic effect of monoclonal antibodies targeting the CRGP pathway in chronic migraine prevention after treatment termination up to 12 weeks.

Keyphrases

cancer therapy
drug delivery